First Wave BioPharma shares are trading lower after the company said preliminary data from Phase 2 SPAN trial indicate that it is likely the primary efficacy endpoint was not achieved.
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma announced that preliminary data from its Phase 2 SPAN trial suggest that the primary efficacy endpoint was likely not achieved, causing its shares to trade lower.
July 13, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
First Wave BioPharma's shares are trading lower due to the likely failure to meet the primary efficacy endpoint in its Phase 2 SPAN trial.
The company's shares are trading lower as a direct result of the announcement that the Phase 2 SPAN trial likely did not meet its primary efficacy endpoint. This is a significant setback for the company, as it indicates that the drug being tested may not be as effective as hoped. This could potentially impact the company's future revenue and profitability, leading to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100